112 related articles for article (PubMed ID: 2602650)
1. Risk of secondary acute leukemia and preleukemia after Hodgkin's disease: the Institut Gustave-Roussy experience.
Henry-Amar M; Pellae-Cosset B; Bayle-Weisgerber C; Hayat M; Cosset JM; Carde P; Tubiana M
Recent Results Cancer Res; 1989; 117():270-83. PubMed ID: 2602650
[TBL] [Abstract][Full Text] [Related]
2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
3. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
[TBL] [Abstract][Full Text] [Related]
4. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
van Leeuwen FE; Chorus AM; van den Belt-Dusebout AW; Hagenbeek A; Noyon R; van Kerkhoff EH; Pinedo HM; Somers R
J Clin Oncol; 1994 May; 12(5):1063-73. PubMed ID: 8164031
[TBL] [Abstract][Full Text] [Related]
5. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
Pedersen-Bjergaard J; Ersbøll J; Sørensen HM; Keiding N; Larsen SO; Philip P; Larsen MS; Schultz H; Nissen NI
Ann Intern Med; 1985 Aug; 103(2):195-200. PubMed ID: 4014901
[TBL] [Abstract][Full Text] [Related]
6. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
[TBL] [Abstract][Full Text] [Related]
7. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.
Pedersen-Bjergaard J; Larsen SO
N Engl J Med; 1982 Oct; 307(16):965-71. PubMed ID: 7110299
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease.
Andrieu JM; Ifrah N; Payen C; Fermanian J; Coscas Y; Flandrin G
J Clin Oncol; 1990 Jul; 8(7):1148-54. PubMed ID: 2193118
[TBL] [Abstract][Full Text] [Related]
9. Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study.
Cimino G; Papa G; Tura S; Mazza P; Rossi Ferrini PL; Bosi A; Amadori S; Lo Coco F; D'Arcangelo E; Giannarelli D
J Clin Oncol; 1991 Mar; 9(3):432-7. PubMed ID: 1999712
[TBL] [Abstract][Full Text] [Related]
10. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease.
Tura S; Fiacchini M; Zinzani PL; Brusamolino E; Gobbi PG
J Clin Oncol; 1993 May; 11(5):925-30. PubMed ID: 8487056
[TBL] [Abstract][Full Text] [Related]
11. Acute nonlymphocytic leukemia: onset after treatment for Hodgkin's disease.
Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Sbarbati S; Tombolini V; Mandelli F; D'Arcangelo E; Biagini C
Ann Hematol; 1997 Mar; 74(3):103-10. PubMed ID: 9111422
[TBL] [Abstract][Full Text] [Related]
12. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.
Pedersen-Bjergaard J; Specht L; Larsen SO; Ersbøll J; Struck J; Hansen MM; Hansen HH; Nissen NI
Lancet; 1987 Jul; 2(8550):83-8. PubMed ID: 2885581
[TBL] [Abstract][Full Text] [Related]
13. Acute nonlymphocytic leukemia after treatment for Hodgkin's disease.
Aisenberg AC
Am J Med; 1983 Sep; 75(3):449-54. PubMed ID: 6688502
[TBL] [Abstract][Full Text] [Related]
14. Hodgkin's disease and acute leukemia. Report of eight cases and review of the literature.
Rosner F; Grünwald H
Am J Med; 1975 Mar; 58(3):339-53. PubMed ID: 1090158
[TBL] [Abstract][Full Text] [Related]
15. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study.
Biti GP; Cimino G; Cartoni C; Magrini SM; Anselmo AP; Enrici RM; Bellesi GP; Bosi A; Papa G; Giannarelli D
J Clin Oncol; 1992 Mar; 10(3):378-82. PubMed ID: 1740677
[TBL] [Abstract][Full Text] [Related]
16. The incidence and characteristics of acute myeloid leukaemia arising in Hodgkin's disease.
Larsen J; Brincker H
Scand J Haematol; 1977 Mar; 18(3):197-206. PubMed ID: 265613
[TBL] [Abstract][Full Text] [Related]
17. Sideroblastic anemia as a preleukemic event in patients treated for Hodgkin's disease.
Kitahara M; Cosgriff TM; Eyre HJ
Ann Intern Med; 1980 May; 92(5):625-7. PubMed ID: 6770730
[TBL] [Abstract][Full Text] [Related]
18. Second malignant tumours in childhood Hodgkin's disease.
Jenkin D; Greenberg M; Fitzgerald A
Med Pediatr Oncol; 1996 Jun; 26(6):373-9. PubMed ID: 8614372
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia following treatment of Hodgkin's disease: a review.
Grünwald HW; Rosner F
Cancer; 1982 Aug; 50(4):676-83. PubMed ID: 6953991
[TBL] [Abstract][Full Text] [Related]
20. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
Delwail V; Jais JP; Colonna P; Andrieu JM
Br J Haematol; 2002 Jul; 118(1):189-94. PubMed ID: 12100147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
